Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41506 | 1.00 | LCK (0.50) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL28230152 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL3468306 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL29486326 | 0.98 | LCK (0.49) | LCKKDRJAK3MAPK14PDPK1 | |
| Hydrochloric Acid SCHEMBL17237902 | 0.96 | LCK (0.47) | LCKKDRJAK3MAPK14PDPK1 | |
| Piperazine SCHEMBL4796334 | 0.88 | LCK (0.43) | LCKKDRJAK3MAPK14PDPK1 | |
| Biphenyl SCHEMBL28889831 | 0.85 | ADORA2A (0.51) | LCKKDRJAK3MAPK14EGFR | |
| SCHEMBL29109657 | 0.84 | METAP2 (0.46) | LCKKDRJAK3MAPK14PDPK1 | |
| Trifluoroacetic Acid SCHEMBL28209915 | 0.82 | ADORA3 (0.40) | LCKKDRJAK3MAPK14DCPS | |
| SCHEMBL28018342 | 0.81 | GRM4 (0.51) | LCKKDRJAK3MAPK14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716684-A1 | SALTS OF AMINO QUINAZOLINE DERIVATIVES | Chiesi Farmaceutici S.p.A. (IT) | 2026-04-01 | — | — | EP | disclosed |
| EP-4558493-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4547247-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4251620-B1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| EP-4251620-C0 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024240727-A1 | SALTS OF AMINO QUINAZOLINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-11-28 | — | — | WO | disclosed |
| EP-4240363-A4 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4240361-A4 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024083255-A8 | BENZYL OR THIENYLMETHYLENE-SUBSTITUTED AMINOQUINAZOLINE DERIVATIVE AND USE THEREOF AS SOS1 DEGRADATION AGENT | 上海领泰生物医药科技有限公司 | 2024-07-11 | — | — | WO | disclosed |
| US-20240174644-A1 | QUINOXALINE UREA INHIBITORS OF IKK-BETA AND NF-KB | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-30 | — | — | US | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022098807-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098806-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-114395624-A | Methods for treatment and diagnosis of cancer | 基因泰克公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3253390-B1 | AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3976180-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976180-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976179-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976179-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174644-A1 | QUINOXALINE UREA INHIBITORS OF IKK-BETA AND NF-KB | NFKBIA, IKBKB, IKBKG | LCK 1270/4885KDR 4194/4885JAK3 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.